Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides

Stephanie Russell, Raphaël Rahmani, Amy J. Jones, Harriet L. Newson, Kevin Neilde, Ignacio Cotillo, Marzieh Rahmani Khajouei, Lori Ferrins, Sana Qureishi, Nghi Nguyen, Maria S. Martinez-Martinez, Donald F. Weaver, Marcel Kaiser, Jennifer Riley, John Thomas, Manu De Rycker, Kevin D. Read, Gavin R. Flematti, Eileen Ryan, Scott Tanghe & 6 others Ana Rodriguez, Susan A. Charman, Albane Kessler, Vicky M. Avery, Jonathan B. Baell, Matthew J. Piggott

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The parasitic trypanosomes Trypanosoma brucei and T. cruzi are responsible for significant human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease. Drugs currently available to treat these neglected diseases leave much to be desired. Herein we report optimization of a novel class of N-(2-(2-phenylthiazol-4-yl)ethyl)amides, carbamates, and ureas, which rapidly, selectively, and potently kill both species of trypanosome. The mode of action of these compounds is unknown but does not involve CYP51 inhibition. They do, however, exhibit clear structure-activity relationships, consistent across both trypanosome species. Favorable physicochemical parameters place the best compounds in CNS drug-like chemical space but, as a class, they exhibit poor metabolic stability. One of the best compounds (64a) cleared all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved in one mouse. This family of compounds thus shows significant promise for trypanosomiasis drug discovery.

Original languageEnglish
Pages (from-to)9686-9720
Number of pages35
JournalJournal of Medicinal Chemistry
Volume59
Issue number21
DOIs
Publication statusPublished - 10 Nov 2016

Cite this

Russell, S., Rahmani, R., Jones, A. J., Newson, H. L., Neilde, K., Cotillo, I., ... Piggott, M. J. (2016). Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides. Journal of Medicinal Chemistry, 59(21), 9686-9720. https://doi.org/10.1021/acs.jmedchem.6b00442
Russell, Stephanie ; Rahmani, Raphaël ; Jones, Amy J. ; Newson, Harriet L. ; Neilde, Kevin ; Cotillo, Ignacio ; Rahmani Khajouei, Marzieh ; Ferrins, Lori ; Qureishi, Sana ; Nguyen, Nghi ; Martinez-Martinez, Maria S. ; Weaver, Donald F. ; Kaiser, Marcel ; Riley, Jennifer ; Thomas, John ; De Rycker, Manu ; Read, Kevin D. ; Flematti, Gavin R. ; Ryan, Eileen ; Tanghe, Scott ; Rodriguez, Ana ; Charman, Susan A. ; Kessler, Albane ; Avery, Vicky M. ; Baell, Jonathan B. ; Piggott, Matthew J. / Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 21. pp. 9686-9720.
@article{d82f82ed56e546e89a17eb9f67d27457,
title = "Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides",
abstract = "The parasitic trypanosomes Trypanosoma brucei and T. cruzi are responsible for significant human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease. Drugs currently available to treat these neglected diseases leave much to be desired. Herein we report optimization of a novel class of N-(2-(2-phenylthiazol-4-yl)ethyl)amides, carbamates, and ureas, which rapidly, selectively, and potently kill both species of trypanosome. The mode of action of these compounds is unknown but does not involve CYP51 inhibition. They do, however, exhibit clear structure-activity relationships, consistent across both trypanosome species. Favorable physicochemical parameters place the best compounds in CNS drug-like chemical space but, as a class, they exhibit poor metabolic stability. One of the best compounds (64a) cleared all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved in one mouse. This family of compounds thus shows significant promise for trypanosomiasis drug discovery.",
author = "Stephanie Russell and Rapha{\"e}l Rahmani and Jones, {Amy J.} and Newson, {Harriet L.} and Kevin Neilde and Ignacio Cotillo and {Rahmani Khajouei}, Marzieh and Lori Ferrins and Sana Qureishi and Nghi Nguyen and Martinez-Martinez, {Maria S.} and Weaver, {Donald F.} and Marcel Kaiser and Jennifer Riley and John Thomas and {De Rycker}, Manu and Read, {Kevin D.} and Flematti, {Gavin R.} and Eileen Ryan and Scott Tanghe and Ana Rodriguez and Charman, {Susan A.} and Albane Kessler and Avery, {Vicky M.} and Baell, {Jonathan B.} and Piggott, {Matthew J.}",
year = "2016",
month = "11",
day = "10",
doi = "10.1021/acs.jmedchem.6b00442",
language = "English",
volume = "59",
pages = "9686--9720",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "AMER CHEMICAL SOC",
number = "21",

}

Russell, S, Rahmani, R, Jones, AJ, Newson, HL, Neilde, K, Cotillo, I, Rahmani Khajouei, M, Ferrins, L, Qureishi, S, Nguyen, N, Martinez-Martinez, MS, Weaver, DF, Kaiser, M, Riley, J, Thomas, J, De Rycker, M, Read, KD, Flematti, GR, Ryan, E, Tanghe, S, Rodriguez, A, Charman, SA, Kessler, A, Avery, VM, Baell, JB & Piggott, MJ 2016, 'Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides' Journal of Medicinal Chemistry, vol. 59, no. 21, pp. 9686-9720. https://doi.org/10.1021/acs.jmedchem.6b00442

Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides. / Russell, Stephanie; Rahmani, Raphaël; Jones, Amy J.; Newson, Harriet L.; Neilde, Kevin; Cotillo, Ignacio; Rahmani Khajouei, Marzieh; Ferrins, Lori; Qureishi, Sana; Nguyen, Nghi; Martinez-Martinez, Maria S.; Weaver, Donald F.; Kaiser, Marcel; Riley, Jennifer; Thomas, John; De Rycker, Manu; Read, Kevin D.; Flematti, Gavin R.; Ryan, Eileen; Tanghe, Scott; Rodriguez, Ana; Charman, Susan A.; Kessler, Albane; Avery, Vicky M.; Baell, Jonathan B.; Piggott, Matthew J.

In: Journal of Medicinal Chemistry, Vol. 59, No. 21, 10.11.2016, p. 9686-9720.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides

AU - Russell, Stephanie

AU - Rahmani, Raphaël

AU - Jones, Amy J.

AU - Newson, Harriet L.

AU - Neilde, Kevin

AU - Cotillo, Ignacio

AU - Rahmani Khajouei, Marzieh

AU - Ferrins, Lori

AU - Qureishi, Sana

AU - Nguyen, Nghi

AU - Martinez-Martinez, Maria S.

AU - Weaver, Donald F.

AU - Kaiser, Marcel

AU - Riley, Jennifer

AU - Thomas, John

AU - De Rycker, Manu

AU - Read, Kevin D.

AU - Flematti, Gavin R.

AU - Ryan, Eileen

AU - Tanghe, Scott

AU - Rodriguez, Ana

AU - Charman, Susan A.

AU - Kessler, Albane

AU - Avery, Vicky M.

AU - Baell, Jonathan B.

AU - Piggott, Matthew J.

PY - 2016/11/10

Y1 - 2016/11/10

N2 - The parasitic trypanosomes Trypanosoma brucei and T. cruzi are responsible for significant human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease. Drugs currently available to treat these neglected diseases leave much to be desired. Herein we report optimization of a novel class of N-(2-(2-phenylthiazol-4-yl)ethyl)amides, carbamates, and ureas, which rapidly, selectively, and potently kill both species of trypanosome. The mode of action of these compounds is unknown but does not involve CYP51 inhibition. They do, however, exhibit clear structure-activity relationships, consistent across both trypanosome species. Favorable physicochemical parameters place the best compounds in CNS drug-like chemical space but, as a class, they exhibit poor metabolic stability. One of the best compounds (64a) cleared all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved in one mouse. This family of compounds thus shows significant promise for trypanosomiasis drug discovery.

AB - The parasitic trypanosomes Trypanosoma brucei and T. cruzi are responsible for significant human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease. Drugs currently available to treat these neglected diseases leave much to be desired. Herein we report optimization of a novel class of N-(2-(2-phenylthiazol-4-yl)ethyl)amides, carbamates, and ureas, which rapidly, selectively, and potently kill both species of trypanosome. The mode of action of these compounds is unknown but does not involve CYP51 inhibition. They do, however, exhibit clear structure-activity relationships, consistent across both trypanosome species. Favorable physicochemical parameters place the best compounds in CNS drug-like chemical space but, as a class, they exhibit poor metabolic stability. One of the best compounds (64a) cleared all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved in one mouse. This family of compounds thus shows significant promise for trypanosomiasis drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=84994894955&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00442

DO - 10.1021/acs.jmedchem.6b00442

M3 - Article

VL - 59

SP - 9686

EP - 9720

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 21

ER -